A groundbreaking medication known as vorasidenib has demonstrated its efficacy in slowing down the progression of glioma, a highly lethal form of brain cancer. The drug received approval from the U.S. Food and Drug Administration (FDA) in June 2023.
Glioma originates in the glial cells, which play a crucial role in supporting and safeguarding nerve cells within the brain. Among adult brain cancers, glioma is the most prevalent category, encompassing various types that can be classified based on their growth rate or grade.
Low-grade gliomas tend to exhibit slow growth and may remain asymptomatic for several years. Conversely, high-grade gliomas exhibit rapid growth and can cause severe symptoms like seizures, headaches, and cognitive impairments.
The standard approach for treating glioma involves surgical intervention to remove as much of the tumour as possible. Radiation therapy and chemotherapy are often administered following surgery to eradicate any remaining cancer cells.
Vorasidenib is a targeted therapy drug designed to impede the formation of new blood vessels that tumors rely on for sustenance. In a clinical trial involving patients with recurrent or progressive glioblastoma, a high-grade glioma, vorasidenib successfully delayed the advancement of glioma.
During the trial, patients receiving vorasidenib had an average survival of 17.2 months, compared to 15.1 months for those who received a placebo. Vorasidenib demonstrated good tolerability, with fatigue, nausea, and vomiting being the most commonly reported side effects.
The FDA’s approval of vorasidenib represents a significant breakthrough in glioma treatment, offering a fresh alternative for patients grappling with this devastating form of cancer.
Here are additional details regarding vorasidenib:
- Novartis markets the drug under the brand name Gliadel.
- Vorasidenib is taken orally once daily in capsule form.
- Fatigue, nausea, and vomiting are the most frequently observed side effects of vorasidenib.
- Pregnant or breastfeeding women should refrain from using vorasidenib.